​

Bio-Path (BPTH) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

BPTH Stock Rating

Bio-Path stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

BPTH Price Target Upside V Benchmarks

TypeNameUpside
StockBio-Path-
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.15$0.15$0.15
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 251----1
Jun, 251----1
May, 251----1
Apr, 251----1
Mar, 251----1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 18, 2022H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-65 $-51 $-37 $-23 $-9 $5 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-56.44$-33.64$-4.12----
Avg Forecast$-60.80$-33.40$-3.17$-1.55$-1.48$-1.44$1.70
High Forecast$-60.80$-33.40$-3.17$-1.55$-1.48$-1.44$1.70
Low Forecast$-60.80$-33.40$-3.17$-1.55$-1.48$-1.44$1.70
Surprise %-7.17%0.72%29.97%----

Revenue Forecast

$20M $33M $46M $59M $72M $85M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$81.44M--$21.61M$40.05M$39.84M$55.80M
High Forecast$81.44M--$21.61M$40.05M$39.84M$55.80M
Low Forecast$81.44M--$21.61M$40.05M$39.84M$55.80M
Surprise %-------

Net Income Forecast

$-30M $-23M $-16M $-9M $-2M $5M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.86M$-16.08M$-9.89M----
Avg Forecast$-29.06M$-15.97M$-1.52M$-740.90K$-707.44K$-688.32K$812.60K
High Forecast$-29.06M$-15.97M$-1.52M$-740.90K$-707.44K$-688.32K$812.60K
Low Forecast$-29.06M$-15.97M$-1.52M$-740.90K$-707.44K$-688.32K$812.60K
Surprise %-62.65%0.71%552.96%----

BPTH Forecast FAQ

Is Bio-Path stock a buy?

Bio-Path stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bio-Path is a favorable investment for most analysts.

What is Bio-Path's price target?

Bio-Path's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.15.

How does Bio-Path stock forecast compare to its benchmarks?

Bio-Path's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Bio-Path over the past three months?

  • July 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Bio-Path’s EPS forecast?

Bio-Path's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.55, marking a -62.38% decrease from the reported $-4.12 in 2024. Estimates for the following years are $-1.48 in 2026, $-1.44 in 2027, and $1.7 in 2028.

What is Bio-Path’s revenue forecast?

Bio-Path's average annual revenue forecast for its fiscal year ending in December 2025 is $21.61M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $40.06M, followed by $39.84M for 2027, and $55.8M for 2028.

What is Bio-Path’s net income forecast?

Bio-Path's net income forecast for the fiscal year ending in December 2025 stands at $-741K, representing a -92.51% decrease from the reported $-9.894M in 2024. Projections indicate $-707K in 2026, $-688K in 2027, and $812.6K in 2028.